Clindamycin Efficacy for Cutibacterium acnes Shoulder Device-Related Infections
Clindamycin is an antibiotic with high bioavailability and appropriate bone diffusion, often proposed as an alternative in guidelines for C. acnes prosthetic joint infections. We aimed to evaluate the efficacy of clindamycin in the treatment of C. acnes shoulder implant joint infections (SIJI).
METHODS: A retrospective analysis was conducted at the University Hospital of Nice (France) between 2010 and 2019. We included patients with one shoulder implant surgical procedure and at least one C. acnes positive sample. We selected the C. acnes SIJI according to French and international recommendations. The primary endpoint was favorable outcome of C. acnes SIJI treatment after at least 1-year follow-up in the clindamycin group compared to another therapeutic group.
RESULTS: Forty-eight SIJI were identified and 33 were treated with clindamycin, among which 25 were treated with monotherapy. The median duration of clindamycin antibiotherapy was 6 weeks. The average follow-up was 45 months; one patient was lost to follow-up. Twenty-seven patients out of 33 (82%) were cured with clindamycin, compared to 9/12 (75%) with other antibiotics. The rate of favorable outcomes increased to 27/31 (87%) with clindamycin and to 9/10 (90%) for other antibiotics when no septic revision strategies were excluded (P = 1.00).
CONCLUSIONS: The therapeutic strategy based on one- or two-stage revision associated with 6 weeks of clindamycin seems to be effective.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Antibiotics (Basel, Switzerland) - 11(2022), 5 vom: 30. Apr. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Courdurié, Audrey [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Clindamycin |
|---|
| Anmerkungen: |
Date Revised 16.07.2022 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/antibiotics11050608 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM341475327 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM341475327 | ||
| 003 | DE-627 | ||
| 005 | 20231226011849.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/antibiotics11050608 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1138.xml |
| 035 | |a (DE-627)NLM341475327 | ||
| 035 | |a (NLM)35625252 | ||
| 035 | |a (PII)608 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Courdurié, Audrey |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clindamycin Efficacy for Cutibacterium acnes Shoulder Device-Related Infections |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 16.07.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Clindamycin is an antibiotic with high bioavailability and appropriate bone diffusion, often proposed as an alternative in guidelines for C. acnes prosthetic joint infections. We aimed to evaluate the efficacy of clindamycin in the treatment of C. acnes shoulder implant joint infections (SIJI) | ||
| 520 | |a METHODS: A retrospective analysis was conducted at the University Hospital of Nice (France) between 2010 and 2019. We included patients with one shoulder implant surgical procedure and at least one C. acnes positive sample. We selected the C. acnes SIJI according to French and international recommendations. The primary endpoint was favorable outcome of C. acnes SIJI treatment after at least 1-year follow-up in the clindamycin group compared to another therapeutic group | ||
| 520 | |a RESULTS: Forty-eight SIJI were identified and 33 were treated with clindamycin, among which 25 were treated with monotherapy. The median duration of clindamycin antibiotherapy was 6 weeks. The average follow-up was 45 months; one patient was lost to follow-up. Twenty-seven patients out of 33 (82%) were cured with clindamycin, compared to 9/12 (75%) with other antibiotics. The rate of favorable outcomes increased to 27/31 (87%) with clindamycin and to 9/10 (90%) for other antibiotics when no septic revision strategies were excluded (P = 1.00) | ||
| 520 | |a CONCLUSIONS: The therapeutic strategy based on one- or two-stage revision associated with 6 weeks of clindamycin seems to be effective | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Cutibacterium acnes | |
| 650 | 4 | |a clindamycin | |
| 650 | 4 | |a shoulder implant | |
| 700 | 1 | |a Lotte, Romain |e verfasserin |4 aut | |
| 700 | 1 | |a Ruimy, Raymond |e verfasserin |4 aut | |
| 700 | 1 | |a Cauhape, Vincent |e verfasserin |4 aut | |
| 700 | 1 | |a Carles, Michel |e verfasserin |4 aut | |
| 700 | 1 | |a Gauci, Marc-Olivier |e verfasserin |4 aut | |
| 700 | 1 | |a Boileau, Pascal |e verfasserin |4 aut | |
| 700 | 1 | |a Courjon, Johan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Antibiotics (Basel, Switzerland) |d 2012 |g 11(2022), 5 vom: 30. Apr. |w (DE-627)NLM243235135 |x 2079-6382 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2022 |g number:5 |g day:30 |g month:04 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/antibiotics11050608 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2022 |e 5 |b 30 |c 04 | ||